David Kao
Concepts (371)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 34 | 2024 | 2046 | 5.240 |
Why?
| | Machine Learning | 7 | 2024 | 513 | 2.250 |
Why?
| | Stroke Volume | 17 | 2025 | 571 | 2.000 |
Why?
| | Adrenergic beta-Antagonists | 10 | 2025 | 221 | 1.600 |
Why?
| | Methadone | 5 | 2023 | 99 | 1.540 |
Why?
| | Pregnancy Complications, Cardiovascular | 5 | 2022 | 75 | 1.490 |
Why?
| | Buprenorphine | 3 | 2023 | 176 | 1.370 |
Why?
| | Cardiomyopathies | 5 | 2022 | 324 | 1.360 |
Why?
| | United States Food and Drug Administration | 5 | 2024 | 200 | 1.240 |
Why?
| | Decision Support Systems, Clinical | 6 | 2024 | 236 | 1.230 |
Why?
| | Cardiomyopathy, Dilated | 9 | 2025 | 323 | 1.180 |
Why?
| | Pharmacogenetics | 5 | 2024 | 165 | 1.160 |
Why?
| | Adverse Drug Reaction Reporting Systems | 4 | 2024 | 77 | 1.130 |
Why?
| | Arrhythmias, Cardiac | 6 | 2023 | 326 | 1.100 |
Why?
| | Electronic Health Records | 7 | 2024 | 1087 | 1.020 |
Why?
| | Cytochrome P-450 CYP2C19 | 4 | 2024 | 25 | 1.000 |
Why?
| | Propanolamines | 3 | 2019 | 32 | 0.930 |
Why?
| | Hospitalization | 10 | 2024 | 2182 | 0.900 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2024 | 451 | 0.870 |
Why?
| | Workflow | 1 | 2024 | 164 | 0.820 |
Why?
| | Telemedicine | 4 | 2024 | 863 | 0.800 |
Why?
| | Torsades de Pointes | 4 | 2016 | 20 | 0.740 |
Why?
| | Seasons | 1 | 2024 | 541 | 0.740 |
Why?
| | Pulmonary Edema | 1 | 2021 | 112 | 0.710 |
Why?
| | Humans | 85 | 2025 | 136965 | 0.710 |
Why?
| | Coffee | 1 | 2021 | 16 | 0.700 |
Why?
| | Stroke | 2 | 2021 | 1124 | 0.680 |
Why?
| | Pharmacogenomic Testing | 4 | 2022 | 60 | 0.670 |
Why?
| | Defibrillators, Implantable | 2 | 2021 | 304 | 0.660 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2024 | 465 | 0.650 |
Why?
| | Aged | 31 | 2025 | 23803 | 0.630 |
Why?
| | Prosthesis Failure | 1 | 2020 | 123 | 0.610 |
Why?
| | Prosthesis-Related Infections | 1 | 2020 | 98 | 0.600 |
Why?
| | Mobile Applications | 1 | 2021 | 178 | 0.600 |
Why?
| | Long QT Syndrome | 3 | 2016 | 68 | 0.600 |
Why?
| | Device Removal | 1 | 2020 | 135 | 0.600 |
Why?
| | Spironolactone | 1 | 2019 | 34 | 0.590 |
Why?
| | Pacemaker, Artificial | 1 | 2020 | 113 | 0.590 |
Why?
| | United States | 21 | 2024 | 14945 | 0.580 |
Why?
| | Mineralocorticoid Receptor Antagonists | 1 | 2019 | 55 | 0.580 |
Why?
| | Medical Records | 2 | 2019 | 180 | 0.580 |
Why?
| | Coronary Disease | 1 | 2021 | 371 | 0.580 |
Why?
| | Diabetes Mellitus | 2 | 2024 | 1056 | 0.570 |
Why?
| | Biomedical Research | 2 | 2024 | 700 | 0.560 |
Why?
| | Periodicals as Topic | 1 | 2020 | 211 | 0.560 |
Why?
| | Mortality | 3 | 2019 | 356 | 0.550 |
Why?
| | Retrospective Studies | 21 | 2024 | 15536 | 0.550 |
Why?
| | Risk Assessment | 8 | 2024 | 3446 | 0.530 |
Why?
| | Hypertension, Pregnancy-Induced | 1 | 2018 | 67 | 0.520 |
Why?
| | Female | 48 | 2025 | 73002 | 0.520 |
Why?
| | Receptors, Transforming Growth Factor beta | 1 | 2017 | 58 | 0.520 |
Why?
| | Hospital Records | 1 | 2016 | 10 | 0.510 |
Why?
| | Atrial Fibrillation | 3 | 2019 | 377 | 0.510 |
Why?
| | Analgesics, Opioid | 2 | 2023 | 1039 | 0.510 |
Why?
| | Ventricular Function, Left | 5 | 2025 | 500 | 0.510 |
Why?
| | Proteoglycans | 1 | 2017 | 107 | 0.500 |
Why?
| | Hospital Mortality | 6 | 2024 | 895 | 0.500 |
Why?
| | Artificial Intelligence | 1 | 2019 | 291 | 0.480 |
Why?
| | Disease Management | 1 | 2020 | 615 | 0.480 |
Why?
| | Survival | 1 | 2015 | 38 | 0.470 |
Why?
| | Tetrazoles | 1 | 2015 | 42 | 0.470 |
Why?
| | Middle Aged | 29 | 2025 | 33226 | 0.470 |
Why?
| | Male | 40 | 2025 | 67386 | 0.460 |
Why?
| | Biphenyl Compounds | 1 | 2015 | 63 | 0.460 |
Why?
| | Muscle Proteins | 2 | 2025 | 229 | 0.460 |
Why?
| | Myocardial Infarction | 3 | 2018 | 1046 | 0.450 |
Why?
| | Research Design | 1 | 2020 | 1114 | 0.430 |
Why?
| | Ventricular Remodeling | 3 | 2025 | 255 | 0.420 |
Why?
| | Loperamide | 2 | 2023 | 11 | 0.420 |
Why?
| | Registries | 2 | 2020 | 2048 | 0.410 |
Why?
| | Myocardium | 3 | 2017 | 895 | 0.410 |
Why?
| | Tachycardia, Ventricular | 1 | 2015 | 169 | 0.400 |
Why?
| | Adult | 28 | 2024 | 37715 | 0.400 |
Why?
| | Polymorphism, Single Nucleotide | 4 | 2017 | 2142 | 0.400 |
Why?
| | Precision Medicine | 6 | 2024 | 415 | 0.400 |
Why?
| | Diet | 1 | 2021 | 1279 | 0.390 |
Why?
| | Legislation, Medical | 1 | 2012 | 10 | 0.390 |
Why?
| | Amiodarone | 1 | 2012 | 26 | 0.380 |
Why?
| | Peripartum Period | 4 | 2022 | 19 | 0.380 |
Why?
| | Phenotype | 5 | 2025 | 3148 | 0.380 |
Why?
| | Patient Readmission | 1 | 2018 | 699 | 0.370 |
Why?
| | Quality Improvement | 2 | 2020 | 1178 | 0.370 |
Why?
| | Anti-Arrhythmia Agents | 1 | 2012 | 109 | 0.370 |
Why?
| | Heart Arrest | 4 | 2019 | 336 | 0.350 |
Why?
| | Catheter Ablation | 1 | 2015 | 330 | 0.350 |
Why?
| | Sex Factors | 4 | 2024 | 2060 | 0.350 |
Why?
| | Pyrazines | 2 | 2008 | 85 | 0.350 |
Why?
| | Treatment Outcome | 10 | 2025 | 10664 | 0.350 |
Why?
| | Triazoles | 2 | 2008 | 150 | 0.340 |
Why?
| | Cardiovascular Diseases | 5 | 2024 | 2115 | 0.330 |
Why?
| | Transfusion Reaction | 1 | 2011 | 60 | 0.330 |
Why?
| | Forecasting | 2 | 2024 | 386 | 0.330 |
Why?
| | Postoperative Complications | 2 | 2020 | 2622 | 0.330 |
Why?
| | Heart-Assist Devices | 1 | 2016 | 545 | 0.330 |
Why?
| | Echocardiography | 3 | 2024 | 639 | 0.330 |
Why?
| | Insurance, Health | 1 | 2012 | 287 | 0.320 |
Why?
| | Patient Transfer | 1 | 2012 | 174 | 0.320 |
Why?
| | Patient Discharge | 2 | 2021 | 901 | 0.320 |
Why?
| | Databases, Factual | 5 | 2020 | 1367 | 0.310 |
Why?
| | Anemia | 1 | 2011 | 171 | 0.310 |
Why?
| | Thiazolidinediones | 1 | 2010 | 137 | 0.300 |
Why?
| | Risk Factors | 9 | 2024 | 10363 | 0.300 |
Why?
| | Aged, 80 and over | 7 | 2024 | 7559 | 0.300 |
Why?
| | Genotype | 3 | 2024 | 1872 | 0.300 |
Why?
| | Marketing | 1 | 2008 | 33 | 0.300 |
Why?
| | Rhabdomyolysis | 1 | 2008 | 21 | 0.290 |
Why?
| | Renal Insufficiency | 1 | 2011 | 160 | 0.290 |
Why?
| | Simvastatin | 1 | 2008 | 60 | 0.290 |
Why?
| | Heart Ventricles | 4 | 2017 | 738 | 0.290 |
Why?
| | Receptors, Adrenergic, beta-1 | 4 | 2019 | 23 | 0.290 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2008 | 46 | 0.280 |
Why?
| | Heart Rate | 3 | 2025 | 794 | 0.280 |
Why?
| | Length of Stay | 4 | 2024 | 1192 | 0.280 |
Why?
| | Electrocardiography | 4 | 2019 | 607 | 0.270 |
Why?
| | Cytochrome P-450 CYP2D6 | 3 | 2022 | 30 | 0.270 |
Why?
| | Drug Industry | 1 | 2008 | 109 | 0.270 |
Why?
| | Kaplan-Meier Estimate | 3 | 2016 | 868 | 0.270 |
Why?
| | Proportional Hazards Models | 4 | 2021 | 1251 | 0.270 |
Why?
| | Practice Patterns, Physicians' | 3 | 2020 | 1295 | 0.260 |
Why?
| | Pharmacovigilance | 2 | 2024 | 23 | 0.260 |
Why?
| | Elective Surgical Procedures | 2 | 2020 | 180 | 0.250 |
Why?
| | Follow-Up Studies | 6 | 2024 | 5048 | 0.250 |
Why?
| | Incidence | 5 | 2024 | 2793 | 0.250 |
Why?
| | Biological Specimen Banks | 3 | 2024 | 100 | 0.250 |
Why?
| | Emergency Service, Hospital | 2 | 2020 | 2080 | 0.240 |
Why?
| | Patient Reported Outcome Measures | 2 | 2020 | 399 | 0.240 |
Why?
| | Gene Expression Regulation | 1 | 2015 | 2574 | 0.240 |
Why?
| | Cause of Death | 2 | 2019 | 428 | 0.230 |
Why?
| | Glucose | 1 | 2010 | 1029 | 0.220 |
Why?
| | New York | 1 | 2024 | 123 | 0.220 |
Why?
| | Diabetic Cardiomyopathies | 1 | 2024 | 35 | 0.220 |
Why?
| | Pandemics | 3 | 2022 | 1630 | 0.220 |
Why?
| | Young Adult | 9 | 2022 | 13218 | 0.210 |
Why?
| | Pregnancy | 6 | 2022 | 6736 | 0.210 |
Why?
| | Acute Kidney Injury | 2 | 2008 | 802 | 0.210 |
Why?
| | Diphenoxylate | 1 | 2023 | 5 | 0.210 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2021 | 1460 | 0.210 |
Why?
| | Adolescent | 10 | 2020 | 21471 | 0.200 |
Why?
| | Nonprescription Drugs | 1 | 2023 | 63 | 0.200 |
Why?
| | Monitoring, Physiologic | 1 | 2024 | 266 | 0.190 |
Why?
| | Heart Defects, Congenital | 2 | 2020 | 828 | 0.190 |
Why?
| | Prognosis | 5 | 2020 | 3931 | 0.190 |
Why?
| | Medicare | 2 | 2020 | 785 | 0.190 |
Why?
| | Naltrexone | 1 | 2023 | 97 | 0.190 |
Why?
| | Insulin Resistance | 1 | 2010 | 1226 | 0.180 |
Why?
| | Time Factors | 3 | 2020 | 6786 | 0.180 |
Why?
| | Speech | 1 | 2021 | 70 | 0.170 |
Why?
| | Red Meat | 1 | 2021 | 19 | 0.170 |
Why?
| | Smartphone | 1 | 2021 | 89 | 0.170 |
Why?
| | Drug Dosage Calculations | 1 | 2020 | 22 | 0.170 |
Why?
| | Losartan | 1 | 2020 | 14 | 0.170 |
Why?
| | Lisinopril | 1 | 2020 | 13 | 0.170 |
Why?
| | Data Interpretation, Statistical | 2 | 2020 | 357 | 0.170 |
Why?
| | Cardiac Resynchronization Therapy | 1 | 2021 | 40 | 0.170 |
Why?
| | Protective Factors | 1 | 2021 | 94 | 0.170 |
Why?
| | Hypoglycemic Agents | 1 | 2010 | 1298 | 0.170 |
Why?
| | Angioedema | 1 | 2020 | 16 | 0.170 |
Why?
| | Actigraphy | 1 | 2021 | 115 | 0.170 |
Why?
| | Hypertension | 2 | 2020 | 1299 | 0.170 |
Why?
| | Wearable Electronic Devices | 1 | 2021 | 53 | 0.170 |
Why?
| | American Heart Association | 2 | 2019 | 301 | 0.170 |
Why?
| | Turner Syndrome | 1 | 2021 | 54 | 0.170 |
Why?
| | Referral and Consultation | 2 | 2017 | 779 | 0.160 |
Why?
| | Biological Products | 1 | 2023 | 217 | 0.160 |
Why?
| | Data Accuracy | 1 | 2020 | 65 | 0.160 |
Why?
| | Milk | 1 | 2021 | 124 | 0.160 |
Why?
| | California | 2 | 2012 | 437 | 0.160 |
Why?
| | Indans | 1 | 2020 | 12 | 0.160 |
Why?
| | Oxadiazoles | 1 | 2020 | 32 | 0.160 |
Why?
| | Bionics | 1 | 2019 | 12 | 0.160 |
Why?
| | Editorial Policies | 1 | 2020 | 52 | 0.160 |
Why?
| | Medical Futility | 1 | 2019 | 24 | 0.160 |
Why?
| | Medical Informatics | 1 | 2020 | 100 | 0.160 |
Why?
| | Software | 2 | 2015 | 662 | 0.160 |
Why?
| | Fingolimod Hydrochloride | 1 | 2020 | 40 | 0.160 |
Why?
| | Medical Record Linkage | 1 | 2020 | 66 | 0.160 |
Why?
| | Information Storage and Retrieval | 1 | 2020 | 118 | 0.150 |
Why?
| | Prescription Drugs | 1 | 2020 | 114 | 0.150 |
Why?
| | Drug Overdose | 1 | 2023 | 354 | 0.150 |
Why?
| | Multiple Sclerosis, Relapsing-Remitting | 1 | 2020 | 76 | 0.150 |
Why?
| | Drug Prescriptions | 1 | 2021 | 258 | 0.150 |
Why?
| | Sitagliptin Phosphate | 2 | 2008 | 32 | 0.150 |
Why?
| | Medical Order Entry Systems | 1 | 2019 | 43 | 0.150 |
Why?
| | Child Health Services | 1 | 2020 | 188 | 0.150 |
Why?
| | Dose-Response Relationship, Drug | 4 | 2020 | 2015 | 0.150 |
Why?
| | Cohort Studies | 3 | 2021 | 5688 | 0.140 |
Why?
| | Social Determinants of Health | 1 | 2022 | 261 | 0.140 |
Why?
| | Tobacco Use | 1 | 2019 | 63 | 0.140 |
Why?
| | Computer Graphics | 2 | 2015 | 41 | 0.140 |
Why?
| | Cluster Analysis | 1 | 2019 | 513 | 0.140 |
Why?
| | Gene Regulatory Networks | 2 | 2023 | 309 | 0.140 |
Why?
| | Receptors, Histamine H2 | 1 | 2017 | 6 | 0.140 |
Why?
| | Florida | 1 | 2018 | 107 | 0.140 |
Why?
| | Advisory Committees | 1 | 2019 | 217 | 0.140 |
Why?
| | Porins | 1 | 1997 | 17 | 0.130 |
Why?
| | Neisseria gonorrhoeae | 1 | 1997 | 28 | 0.130 |
Why?
| | Prospective Studies | 4 | 2021 | 7512 | 0.130 |
Why?
| | Dyslipidemias | 1 | 2019 | 178 | 0.130 |
Why?
| | Academic Medical Centers | 1 | 2020 | 504 | 0.130 |
Why?
| | Nursing Assessment | 1 | 2017 | 57 | 0.130 |
Why?
| | Heart Diseases | 1 | 2020 | 325 | 0.130 |
Why?
| | Antihypertensive Agents | 1 | 2020 | 495 | 0.130 |
Why?
| | Pressure Ulcer | 1 | 2017 | 46 | 0.130 |
Why?
| | Patient Participation | 1 | 2020 | 424 | 0.130 |
Why?
| | Cardiology | 1 | 2019 | 271 | 0.130 |
Why?
| | Population Surveillance | 1 | 2020 | 487 | 0.130 |
Why?
| | Hospitals, Teaching | 1 | 2017 | 113 | 0.130 |
Why?
| | Tilidine | 1 | 2016 | 2 | 0.130 |
Why?
| | Double-Blind Method | 3 | 2025 | 1904 | 0.120 |
Why?
| | Consensus | 1 | 2019 | 675 | 0.120 |
Why?
| | Genetic Markers | 1 | 2017 | 346 | 0.120 |
Why?
| | Oxycodone | 1 | 2016 | 48 | 0.120 |
Why?
| | Databases, Genetic | 1 | 2017 | 239 | 0.120 |
Why?
| | Rheumatic Heart Disease | 1 | 2015 | 7 | 0.120 |
Why?
| | Sex Distribution | 1 | 2016 | 373 | 0.120 |
Why?
| | Rheumatic Fever | 1 | 2015 | 10 | 0.120 |
Why?
| | Cholesterol Ester Transfer Proteins | 1 | 2015 | 18 | 0.120 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2015 | 38 | 0.120 |
Why?
| | Hospitals, Low-Volume | 1 | 2015 | 23 | 0.110 |
Why?
| | Angiotensin II | 1 | 2015 | 96 | 0.110 |
Why?
| | Naloxone | 1 | 2016 | 121 | 0.110 |
Why?
| | Gene Expression Profiling | 3 | 2017 | 1747 | 0.110 |
Why?
| | Computational Biology | 2 | 2017 | 647 | 0.110 |
Why?
| | Hospitals, High-Volume | 1 | 2015 | 43 | 0.110 |
Why?
| | Immunosuppressive Agents | 1 | 2020 | 861 | 0.110 |
Why?
| | Marijuana Use | 1 | 2018 | 205 | 0.110 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2017 | 756 | 0.110 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2020 | 482 | 0.110 |
Why?
| | United Kingdom | 1 | 2015 | 315 | 0.110 |
Why?
| | Mothers | 1 | 2020 | 758 | 0.110 |
Why?
| | Biomarkers | 2 | 2024 | 4095 | 0.110 |
Why?
| | International Classification of Diseases | 1 | 2015 | 136 | 0.110 |
Why?
| | Age Factors | 2 | 2019 | 3258 | 0.110 |
Why?
| | Comorbidity | 1 | 2019 | 1626 | 0.110 |
Why?
| | Chronic Disease | 2 | 2020 | 1774 | 0.100 |
Why?
| | Narcotic Antagonists | 1 | 2015 | 181 | 0.100 |
Why?
| | Gene Expression | 2 | 2017 | 1480 | 0.100 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2020 | 362 | 0.100 |
Why?
| | Down-Regulation | 1 | 2015 | 633 | 0.100 |
Why?
| | MicroRNAs | 2 | 2017 | 677 | 0.100 |
Why?
| | Cholesterol | 1 | 2015 | 411 | 0.100 |
Why?
| | Coronary Artery Disease | 1 | 2019 | 698 | 0.100 |
Why?
| | Myocytes, Cardiac | 1 | 2017 | 505 | 0.100 |
Why?
| | Federal Government | 1 | 2012 | 27 | 0.100 |
Why?
| | RNA, Messenger | 2 | 2017 | 2788 | 0.090 |
Why?
| | Drug Resistance | 1 | 2012 | 145 | 0.090 |
Why?
| | Area Under Curve | 1 | 2012 | 303 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 2 | 2017 | 2371 | 0.090 |
Why?
| | Predictive Value of Tests | 1 | 2017 | 1999 | 0.090 |
Why?
| | Patient Safety | 1 | 2015 | 313 | 0.090 |
Why?
| | Colorado | 4 | 2024 | 4542 | 0.090 |
Why?
| | Opiate Substitution Treatment | 1 | 2013 | 155 | 0.090 |
Why?
| | Gastrointestinal Hemorrhage | 1 | 2012 | 133 | 0.090 |
Why?
| | Anti-Retroviral Agents | 1 | 2013 | 240 | 0.090 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 1027 | 0.090 |
Why?
| | Pregnancy Outcome | 1 | 2013 | 416 | 0.090 |
Why?
| | Survival Rate | 1 | 2015 | 1882 | 0.080 |
Why?
| | Bayes Theorem | 1 | 2012 | 410 | 0.080 |
Why?
| | Managed Care Programs | 2 | 2022 | 141 | 0.080 |
Why?
| | Genome-Wide Association Study | 1 | 2017 | 1395 | 0.080 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2012 | 228 | 0.080 |
Why?
| | Delivery of Health Care | 1 | 2017 | 957 | 0.080 |
Why?
| | Emergency Medical Services | 1 | 2015 | 556 | 0.080 |
Why?
| | Multivariate Analysis | 1 | 2012 | 1484 | 0.070 |
Why?
| | Severity of Illness Index | 1 | 2017 | 2809 | 0.070 |
Why?
| | Pharmacogenomic Variants | 2 | 2019 | 33 | 0.070 |
Why?
| | Drug Approval | 1 | 2008 | 86 | 0.070 |
Why?
| | Primary Health Care | 1 | 2019 | 1775 | 0.070 |
Why?
| | Vasodilator Agents | 1 | 2010 | 319 | 0.070 |
Why?
| | Logistic Models | 1 | 2012 | 2066 | 0.070 |
Why?
| | Kidney Function Tests | 1 | 2007 | 157 | 0.070 |
Why?
| | Animals | 3 | 2023 | 36882 | 0.060 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2008 | 247 | 0.060 |
Why?
| | Zimbabwe | 2 | 2017 | 58 | 0.060 |
Why?
| | Drug Therapy, Combination | 1 | 2008 | 1022 | 0.060 |
Why?
| | Opioid-Related Disorders | 1 | 2013 | 532 | 0.060 |
Why?
| | Models, Biological | 1 | 2012 | 1780 | 0.060 |
Why?
| | Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels | 1 | 2025 | 35 | 0.060 |
Why?
| | Case-Control Studies | 1 | 2012 | 3556 | 0.060 |
Why?
| | Psychological Tests | 1 | 2005 | 135 | 0.050 |
Why?
| | Osteoporosis, Postmenopausal | 1 | 2004 | 42 | 0.050 |
Why?
| | Potassium Channels | 1 | 2025 | 147 | 0.050 |
Why?
| | Depression | 2 | 2022 | 1454 | 0.050 |
Why?
| | Mandible | 1 | 2004 | 68 | 0.050 |
Why?
| | Cross-Sectional Studies | 3 | 2022 | 5530 | 0.050 |
Why?
| | Receptors, Adrenergic | 1 | 2023 | 21 | 0.050 |
Why?
| | Drug Administration Schedule | 2 | 2020 | 749 | 0.050 |
Why?
| | Cardiovascular Agents | 1 | 2025 | 152 | 0.050 |
Why?
| | Algorithms | 3 | 2020 | 1700 | 0.050 |
Why?
| | Carcinoembryonic Antigen | 1 | 2002 | 36 | 0.050 |
Why?
| | Antigens, Differentiation | 1 | 2002 | 81 | 0.050 |
Why?
| | Child | 5 | 2020 | 21760 | 0.050 |
Why?
| | Antigens, Bacterial | 1 | 2002 | 127 | 0.040 |
Why?
| | Electronic Prescribing | 1 | 2021 | 3 | 0.040 |
Why?
| | Cell Adhesion Molecules | 1 | 2002 | 176 | 0.040 |
Why?
| | Vitamin K Epoxide Reductases | 1 | 2020 | 12 | 0.040 |
Why?
| | Health Services Misuse | 1 | 2020 | 32 | 0.040 |
Why?
| | Insurance Claim Reporting | 1 | 2020 | 24 | 0.040 |
Why?
| | Antidepressive Agents | 1 | 2022 | 242 | 0.040 |
Why?
| | Lymphocyte Count | 1 | 2020 | 147 | 0.040 |
Why?
| | Morbidity | 1 | 2020 | 319 | 0.040 |
Why?
| | Antigens, Neoplasm | 1 | 2002 | 316 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2002 | 496 | 0.040 |
Why?
| | Metoprolol | 1 | 2019 | 21 | 0.040 |
Why?
| | Antineoplastic Agents | 1 | 2010 | 2111 | 0.040 |
Why?
| | Grounded Theory | 1 | 2019 | 36 | 0.040 |
Why?
| | Antigens, CD | 1 | 2002 | 527 | 0.040 |
Why?
| | Aftercare | 1 | 2020 | 208 | 0.040 |
Why?
| | Bias | 1 | 2020 | 222 | 0.040 |
Why?
| | Genomics | 1 | 2024 | 804 | 0.040 |
Why?
| | HIV Infections | 1 | 2013 | 2898 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2023 | 2156 | 0.040 |
Why?
| | Coronary Angiography | 1 | 2020 | 314 | 0.030 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2020 | 281 | 0.030 |
Why?
| | Amino Acid Sequence | 2 | 2002 | 2139 | 0.030 |
Why?
| | Static Electricity | 1 | 1997 | 117 | 0.030 |
Why?
| | Exercise Test | 1 | 2020 | 617 | 0.030 |
Why?
| | Molecular Sequence Data | 2 | 2002 | 2900 | 0.030 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2017 | 79 | 0.030 |
Why?
| | Inpatients | 1 | 2021 | 496 | 0.030 |
Why?
| | Focus Groups | 1 | 2019 | 535 | 0.030 |
Why?
| | Frail Elderly | 1 | 2017 | 130 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2017 | 347 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2020 | 1310 | 0.030 |
Why?
| | Puerperal Disorders | 1 | 2016 | 31 | 0.030 |
Why?
| | Metabolic Networks and Pathways | 1 | 2017 | 182 | 0.030 |
Why?
| | World Health Organization | 1 | 2016 | 124 | 0.030 |
Why?
| | Physician-Patient Relations | 1 | 2020 | 577 | 0.030 |
Why?
| | Neoplasms | 1 | 2010 | 2698 | 0.030 |
Why?
| | Drug Combinations | 1 | 2016 | 341 | 0.030 |
Why?
| | Decision Trees | 1 | 2015 | 88 | 0.030 |
Why?
| | Data Mining | 1 | 2015 | 116 | 0.030 |
Why?
| | Cell Membrane | 1 | 1997 | 710 | 0.030 |
Why?
| | Blood Pressure | 1 | 2020 | 1786 | 0.030 |
Why?
| | Biopsy | 1 | 2017 | 1083 | 0.030 |
Why?
| | Pediatrics | 1 | 2020 | 1061 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2020 | 3266 | 0.020 |
Why?
| | Models, Genetic | 1 | 2015 | 586 | 0.020 |
Why?
| | Infant | 2 | 2015 | 9392 | 0.020 |
Why?
| | Liver | 1 | 2020 | 1867 | 0.020 |
Why?
| | Mass Screening | 2 | 2013 | 1295 | 0.020 |
Why?
| | Anthracyclines | 1 | 2010 | 42 | 0.020 |
Why?
| | Child, Preschool | 2 | 2015 | 10952 | 0.020 |
Why?
| | Trastuzumab | 1 | 2010 | 96 | 0.020 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2010 | 96 | 0.020 |
Why?
| | Signal Transduction | 1 | 2023 | 5047 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2015 | 1019 | 0.020 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 195 | 0.020 |
Why?
| | Program Evaluation | 1 | 2013 | 907 | 0.020 |
Why?
| | Apoptosis | 1 | 2017 | 2542 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2007 | 197 | 0.020 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2007 | 97 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2007 | 392 | 0.020 |
Why?
| | Ultrasonography | 1 | 2010 | 761 | 0.020 |
Why?
| | Mice | 1 | 2023 | 17705 | 0.020 |
Why?
| | Creatinine | 1 | 2007 | 486 | 0.010 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2010 | 798 | 0.010 |
Why?
| | Hospitals, University | 1 | 2005 | 178 | 0.010 |
Why?
| | Dentists | 1 | 2004 | 21 | 0.010 |
Why?
| | Femur Neck | 1 | 2004 | 61 | 0.010 |
Why?
| | Bone Diseases, Metabolic | 1 | 2004 | 63 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2010 | 1412 | 0.010 |
Why?
| | Absorptiometry, Photon | 1 | 2004 | 264 | 0.010 |
Why?
| | Nurses | 1 | 2005 | 184 | 0.010 |
Why?
| | Heparan Sulfate Proteoglycans | 1 | 2002 | 25 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2004 | 1301 | 0.010 |
Why?
| | HeLa Cells | 1 | 2002 | 632 | 0.010 |
Why?
| | Bone Density | 1 | 2004 | 488 | 0.010 |
Why?
| | Binding Sites | 1 | 2002 | 1310 | 0.010 |
Why?
| | Clinical Competence | 1 | 2005 | 1114 | 0.010 |
Why?
| | Physicians | 1 | 2005 | 921 | 0.010 |
Why?
|
|
Kao's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|